Rapid Point-of-Care Diagnostic for Early Detection of Dengue Infection

用于早期发现登革热感染的快速护理点诊断

• 批准号: 8905431
• 负责人: HyunDae Cho
• 金额: $ 30.52万
• 依托单位: CROSSLIFE TECHNOLOGIES, INC.
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-05-20 至 2017-02-19
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8905431
• 关键词: Antibodies; Area; Berlin; Biological Assay; Blood; Blood specimen; Buffers; Chemicals; Chemistry; Clinical; Communicable Diseases; Consult; Containment; Country; Cross Infection; Culicidae; Dengue; Dengue Virus; Detection; Development; Devices; Diagnosis; Diagnostic; Disease; Early Diagnosis; Early treatment; Enzymes; Epidemic; Evaluation; Fever; Genetic Materials; Gold; Human; Immobilization; Infection; Laboratories; Lateral; Latin America; Life; Magnetic nanoparticles; Magnetism; Methods; Molecular Diagnosis; Nucleic Acids; Outcome; Paper; Patients; Performance; Phase; Plasma; Pregnancy Tests; Preparation; Public Health; RNA; RNA amplification; RNA purification; Reaction; Relative (related person); Reproducibility; Reverse Transcriptase Polymerase Chain Reaction; Sampling; Self-Administered; Serotyping; Serum; Signal Transduction; Southeastern Asia; Specificity; Techniques; Technology; Testing; Universities; Validation; Virus; Virus Diseases; Whole Blood; assay development; base; chemical transfer reaction; communicable disease diagnosis; cost; design; diagnostic assay; economic impact; effective therapy; improved; innovation; innovative technologies; instrument; instrumentation; nanoparticle; pathogen; point of care; point-of-care diagnostics; public health relevance; rapid detection; reaction rate; rural area; tool; viral RNA

 DESCRIPTION (provided by applicant): Rapid Point-of-Care Diagnostic for Early Detection of Dengue Infection Cross Life Technologies Inc. Dengue viruses (DENV) are one of the most dangerous and significant pathogens in the world, and there are 230 million cases of dengue virus infections per year, mostly in Latin America and Southeast Asia. These mosquito-borne viruses cause periodic explosive epidemics in many tropical and sub-tropical countries. Cross Life technologies' dengue diagnostic is being developed to detect dengue infection early so that patients can be treated effectively. Early and rapid detection of dengue virus (DENV) infection during the febrile period is crucial for proper patient management and containment of the disease. However, current methods for early detection of dengue involve the use of RT-PCR instruments in the laboratory, which may not be available in areas where dengue is endemic, and which may be too slow. Cross Life Technologies (CLT) proposes to develop a Template Assisted Rapid Assay (TARA) diagnostics for detection of dengue viruses in human blood. TARA dengue diagnostic will detect dengue in 15 minutes on a paper strip at the point-of-care (POC) so that patients can be treated rapidly and at low cost. A sensitive nucleic acid POC diagnostic paper dipstick device capable of detecting and identifying the 4 serotypes of dengue virus will be developed in order to facilitate more accurate detection of dengue infection in order to improve public health. We propose the development of a multiplex dengue diagnostic assay using an innovative RNA amplification chemistry. This innovative technology will provide an enzyme-free, PCR-less, instrumentation-free, low-cost, disposable, rapid and sensitive POC dengue diagnostics directly from whole blood samples.

 描述(由申请人提供)：用于早期检测登革热感染的快速护理点诊断跨生命技术公司登革热病毒(DENV)是世界上最危险和最重要的病原体之一，每年有2.3亿登革热病毒感染病例，主要发生在拉丁美洲和东南亚。这些由蚊子传播的病毒会在许多热带和亚热带国家引起周期性的大流行。正在开发跨生命技术公司的登革热诊断方法，以及早发现登革热感染，以便患者能够得到有效治疗。在发烧期间及早和快速检测登革病毒(DENV)感染对于适当的患者管理和疾病控制至关重要。然而，目前早期检测登革热的方法涉及在实验室使用RT-PCR仪器，这在登革热流行的地区可能无法获得，而且可能太慢。跨生命技术公司(CLT)建议开发一种模板辅助快速检测(TARA)诊断方法，用于检测人类血液中的登革热病毒。Tara登革热诊断将在15分钟内在医疗点(POC)的纸条上检测到登革热，以便患者能够以低成本得到快速治疗。为了更准确地检测登革热感染，将开发一种能够检测和识别登革热病毒4种血清型的灵敏核酸POC诊断纸试纸条装置 以改善公众健康。我们建议开发一种使用创新的RNA扩增化学方法的多重登革热诊断方法。这项创新技术将提供一种直接从全血样本中直接诊断POC登革热的无酶、无PCR、无需仪器、低成本、一次性、快速和灵敏的方法。